Untangling the Complexity of Alzheimer Disease With Effective Diagnostic Tools and Novel Treatment Options
Untangling the Complexity of Alzheimer Disease With Effective Diagnostic Tools and Novel Treatment Options is organized by CME Institute of Physicians Postgraduate Press, Inc. (PPP).
Start Date: 08/17/2023
Expiration Date: 08/31/2024
Description:
Join this Team Meeting with Drs Carolyn K. Clevenger, DNP, Associate Dean for Transformative Clinical Practice and Clinical Professor at Nell Hodgson Woodruff School of Nursing; David Geldmacher, MD, Division Director of Memory Disorders and Professor of Neurology at UAB Heersink School of Medicine; and Marc Agronin, MD, Chief Medical Officer of MIND Institute and Behavioral Health at Miami Jewish Health and Affiliate Associate Professor of Psychiatry and Neurology at the UM Miller School of Medicine. In this video, the team discusses the pathogenesis of Alzheimer disease (AD) and the correlating classification of biomarkers that can direct appropriate treatment options. AD is characterized by buildup of toxic amyloid (A) plaques in the brain, the destabilization of tau (T) inside neurons and the formation of neurofibrillary tangles, inflammation, and neurodegeneration (N). With the AT(N) biomarker classification system developed by the National Institute on Aging-Alzheimer’s Association (NIA-AA) research framework, AD can be staged biologically throughout its disease course, including the preclinical stage in which there is biomarker evidence but no symptoms, creating a significant opportunity for early intervention and potentially the prevention of symptom onset. Novel and emerging therapeutics that target amyloid and tau as well as the intracellular process involved in the AD pathology cascade suggest multiple therapeutic approaches in treating patients with AD, and together with new and emerging diagnostic tools, there is a shift in the discussion around AD and the potentiality to engage patients in their own care and change their disease trajectory.
Learning Objectives:
• Identify biomarkers used in the early identification of Alzheimer disease
• Assess the efficacy and safety data of novel investigational therapies for the management of Alzheimer disease
• Implement advancements in diagnostic and screening tools for early Alzheimer disease assessment